Boston Scientific Corp. said late Thursday it has agreed to buy privately held Augmenix Inc. for $500 million in cash and up to an additional $100 million for reaching sales milestones.
Augmenix has developed a therapy to reduce side effects related to prostate-cancer radiotherapy. Sales of the therapy are expected to reach $50 million this year and about $90 million in 2019, Boston Scientific said.
The deal is expected to close early in the fourth quarter, subject to customary closing conditions, and to be immaterial to adjusted per-share earnings this year and the next and accretive by 2020.
Shares of Boston Scientific rose 0.2% in the extended session after ending the regular trading day up 0.7%.
By Claudia Assis
Source: MarketWatch
UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).
GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.
